Biognomics Lab, LLC
Biognomics Lab, LLC was paid $236K by Medicaid between Jan 2022 and May 2023, across 5 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 75% of everything it billed.
33Billing provider infoBIOGNOMICS LAB, LLC
IRVINE, CA 92618
IRVINE, CA 92618
33aNPI1700466745assigned 04/13/2021
33bProvider typeClinical Laboratory Director (Non-physician)
28Total paid$236K
24GClaims6,252
24DCodes billed5
24AFirst – last monthJan 2022 – May 2023
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 4,980 | $229K | |
| 2023 | 1,272 | $7K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 75% | 2,426 | 1,592 | $177K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 18% | 1,995 | 1,277 | $43K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.6% | 506 | 294 | $8K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2.8% | 1,272 | 1,241 | $7K |
| 99072 | <1% | 53 | 50 | $388.80 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVELARDE, ALVIN (OWNER/CHIEF OPERATING OFFICER)